AxoGen Inc. (NASDAQ: AXGN) stock fell -1.62% on Friday to $5.45 against a previous-day closing price of $5.54. With 0.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.28 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $5.51 whereas the lowest price it dropped to was $5.30. The 52-week range on AXGN shows that it touched its highest point at $13.66 and its lowest point at $5.38 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at 0.68.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AXGN was down-trending over the past week, with a drop of -2.33%, but this was down by -3.54% over a month. Three-month performance dropped to -43.17% while six-month performance fell -34.10%. The stock lost -50.99% in the past year, while it has lost -45.39% so far this year. A look at the trailing 12-month EPS for AXGN yields -0.55 with Next year EPS estimates of -0.10. For the next quarter, that number is -0.08. This implies an EPS growth rate of -5.10% for this year and 61.50% for next year.
Float and Shares Shorts:
At present, 42.86 million AXGN shares are outstanding with a float of 39.28 million shares on hand for trading. On Aug 30, 2023, short shares totaled 1.41 million, which was 3.28% higher than short shares on Jul 30, 2023. In addition to Ms. Karen Zaderej as the firm’s Chairman, Pres & CEO, Mr. Peter J. Mariani serves as its Exec. VP & CFO.
Through their ownership of 78.58% of AXGN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 52.23% of AXGN, in contrast to 30.18% held by mutual funds. Shares owned by individuals account for 25.67%. As the largest shareholder in AXGN with 10.31% of the stake, ArrowMark Colorado Holdings LLC holds 4,431,629 shares worth 4,431,629. A second-largest stockholder of AXGN, Soleus Capital Management LP, holds 3,541,298 shares, controlling over 8.24% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in AXGN, holding 2,771,316 shares or 6.45% stake. With a 3.20% stake in AXGN, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,375,595 shares are owned by the mutual fund manager. The Vanguard Explorer Fund, which owns about 2.50% of AXGN stock, is the second-largest Mutual Fund holder. It holds 1,072,597 shares valued at 6.71 million. iShares Russell 2000 ETF holds 2.10% of the stake in AXGN, owning 901,151 shares worth 5.64 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, AXGN reported revenue of $34.45M and operating income of -$7.92M. The EBITDA in the recently reported quarter was -$6.75M and diluted EPS was -$0.18.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AXGN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AXGN analysts setting a high price target of $20.00 and a low target of $11.00, the average target price over the next 12 months is $15.00. Based on these targets, AXGN could surge 266.97% to reach the target high and rise by 101.83% to reach the target low. Reaching the average price target will result in a growth of 175.23% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded AXGN stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 10,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 42 while that of sell transactions has risen to 36 over the past year. The total number of shares bought during that period was 394,880 while 237,018 shares were sold.